Navigation Links
'Alzheimer protein' seems to slow down neurotransmitter production
Date:8/21/2012

How abnormal protein deposits in the brains of Alzheimer's patients disrupt the signalling between nerve cells has now been reported by researchers in Bochum and Munich, led by Dr. Thorsten Mller from the Medizinisches Proteom-Center of the Ruhr-Universitt, in the journal Molecular and Cellular Proteomics. They varied the amount of APP protein and related proteins associated with Alzheimer's disease in cell cultures, and then analysed how this manipulation affected other proteins in the cell. The result: the amount of APP present was related to the amount of an enzyme that is essential for the production of neurotransmitters and therefore for communication amongst nerve cells.

Proteomics: analysing all the proteins of the cells at once

Amyloid plaques are a characteristic feature of Alzheimer's disease. They consist largely of cleavage products of the so-called amyloid precursor protein APP, which occur in excess in the brains of Alzheimer's patients. What role APP plays in healthy people and why the abnormal accumulation of amyloid disrupts the regular functioning of the brain is still largely unclear. To understand the function of APP, the RUB researchers established a new cell model. The new cells produced only a very small amount of APP. What impact this had on all the other proteins of these cells was examined by the researchers through the use of mass spectrometry, among other things. With this method they identified over 2000 proteins and determined their concentrations. They were looking specifically for molecules whose concentrations in the newly established low-APP cells were different than in the reference cells that contained normal amounts of APP.

Abnormal protein able to curb neurotransmitter production

"One candidate has particularly caught our attention, this being the enzyme methionine adenosyltransferase II, alpha, MAT2A for short", Thorsten Mller said. Among other things, the enzyme is crucially involved in the production of neurotransmitters. Low-APP cells contained less MAT2A than the reference cells. To confirm the connection between the "Alzheimer's protein" APP and the neurotransmitter-producing MAT2A, the team studied tissue samples from the brains of deceased Alzheimer's patients and from healthy individuals. In the tissue of the Alzheimer's patients there was less MAT2A than in the healthy samples. These results suggest that APP and MAT2A concentrations are related and are linked to the synthesis of neurotransmitters. "Our results point to a new mechanism by which the defective cleavage of the APP protein in Alzheimer's disease could be directly related to altered neurotransmitter production", Mller said. "As a result, the signal transduction of nerve cells could be disrupted, which, over an extended period, could possibly also cause the death of cells."


'/>"/>
Contact: Dr. Thorsten Mller
thorsten.t.mueller@rub.de
49-234-322-9265
Ruhr-University Bochum
Source:Eurekalert

Related medicine news :

1. Rejected drug may protect against toxic substance common to Alzheimers and Parkinsons diseases
2. Blood test for Alzheimers gaining ground
3. Alzheimers Progression Slower After 80: Study
4. In Mice, Alzheimers-Linked Protein Shows Promise Against MS
5. Artificial butter flavoring ingredient linked to key Alzheimers disease process
6. Spice ingredient in curry emerges as promising basis for an Alzheimers disease medicine
7. Rejected Alzheimers drug shows new potential
8. Scientists Say Blood Test May Help Predict Alzheimers
9. Helping Alzheimers patients stay independent
10. Alzheimers Drug Shows Promise in Early Trial
11. Alzheimers Treatment Shows Promise in Small, 3-Year Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 26, 2017 , ... Amir Qureshi, MD is the first physician in Arkansas ... stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a treatment ... in Arkansas to introduce the most powerful SCS system and the only stretchable lead ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the ... narrowly passed the U.S. House on May 4, would result in 23 million Americans ... continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). , ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a ... announce a new, informational blog post on insurance options. If a Bay Area patient ... may help save time and money. Visiting an in-network provider for a second opinion ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “Cactus Jack: Against ... on so many others. “Cactus Jack: Against All Odds” is the creation of ... Walter D. Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter ...
(Date:5/24/2017)... Hills, CA (PRWEB) , ... May 24, 2017 , ... ... announced today its participation in nVerge 2017 – a one-day technology conference in San ... Altec’s document management solution, which allows users to fully utilize and enhance their Sage ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals ... ), a clinical-stage pharmaceutical company focused on the ... that the Canadian Intellectual Property Office has granted ... Oral Administration of Exenatide". The patent covers Oramed,s ... GLP-1 is an incretin hormone that ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
Breaking Medicine Technology: